Sign In
Buy RHHBY
$49.06
-0.130 (-0.264%)
At Close: Jun 03, 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer's development portfolio is being pres
Roche presents new insights in Alzheimer's disease research across its diagnostics and pharmaceutical portfolios at AAIC
01:00am, Monday, 28'th Jul 2025
Basel, 28 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer's development portfolio is being presented at the Alzheimer's Association International Confer
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
04:40pm, Sunday, 27'th Jul 2025
Swiss drugmaker Roche Holding plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday.
Roche Holding AG (RHHBY) Q2 2025 Earnings Call Transcript
01:44pm, Friday, 25'th Jul 2025
Roche Holding AG (OTCQX:RHHBY) Q2 2025 Earnings Conference Call July 24, 2025 8:00 AM ET Company Participants Alan Hippe - Chief Financial Officer Bruno Eschli - Head of Investor Relations Matthew Sau
Roche Reports 7% 1H25 Sales Growth, Key Drugs Perform Well
11:50am, Thursday, 24'th Jul 2025
RHHBY posts solid first-half 2025 growth on strong drug demand, but pipeline setbacks and biosimilar hits remain headwinds.
Roche: Q2 Earnings - Pipeline Setbacks And U.S. Pressures Undermine Solid Results
11:36am, Thursday, 24'th Jul 2025
Roche Holding AG's Q2 and 1H 2025 earnings will, initially, broadly please the market despite recent pipeline and commercial setbacks. The pharmaceuticals division delivered strong revenue growth, up
Roche Diagnostics showcases science-driven leadership and innovation at ADLM 2025
09:00am, Thursday, 24'th Jul 2025
Lead With Us -- a promise for innovative partnerships, better insights, faster support, and improved healthcare outcomes. INDIANAPOLIS and CHICAGO , July 24, 2025 /PRNewswire/ -- Roche (SIX: RO, ROG;
Roche considering selling drugs directly to US patients, CEO says
06:03am, Thursday, 24'th Jul 2025
Roche is considering selling its prescription medicines in the U.S. directly to consumers to lower costs for patients as part of talks with the U.S. government, which is pressuring drugmakers to cut p
Roche confirms guidance as H1 core operating profit up 6%
01:16am, Thursday, 24'th Jul 2025
Swiss drugmaker Roche reported first-half operating profit up 6% on Thursday at a forecast-beating 12 billion Swiss francs ($15.15 billion) and also confirmed its full-year outlook.
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum with 7% growth (CER) in the first half of 2025
01:00am, Thursday, 24'th Jul 2025
Basel, 24 July 2025 Group sales grew by 7%1 at constant exchange rates (CER; 4% in CHF), driven by strong demand for medicines. Pharmaceuticals Division sales rose by 10% (6% in CHF), with Phesgo (bre
The Roche Associates, Inc. Named “Top Senior Living Marketing Agency 2025”
05:20pm, Wednesday, 23'rd Jul 2025
East Longmeadow, MA, July 23, 2025 (GLOBE NEWSWIRE) -- The Roche Associates, Inc. was recently named “Top Senior Living Marketing Agency for 2025” by Elder Care Review. The Roche Associates, Inc.
Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer's disease
01:10am, Wednesday, 23'rd Jul 2025
Basel, 23 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it has received CE Mark for its Elecsys® pTau181 test to measure phosphorylated Tau (pTau) 181 protein which is an indicator o
European Commission approves Roche's Itovebi for people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation
01:00am, Wednesday, 23'rd Jul 2025
Basel, 23 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Itovebi™ (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant
Roche pauses shipments of Elevidys gene therapy outside the US, Bloomberg News reports
05:42pm, Tuesday, 22'nd Jul 2025
Roche Holding AG paused all shipments of the controversial gene therapy Elevidys, Bloomberg News reported on Tuesday.
Roche's Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)
12:45pm, Tuesday, 22'nd Jul 2025
Basel, 22 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today its Board of Directors' decision to propose to shareholders a modernisation of Roche Holding Ltd's capital structure for approv
